NCT05077800 2026-04-13
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT05973331 2026-02-09
Prospective Validation of an EHR-based Pancreatic Cancer Risk Model
Beth Israel Deaconess Medical Center
Active not recruiting
NCT02336087 2026-02-04
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04539808 2026-01-14
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT03245541 2025-10-07
Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT04986930 2025-01-28
SABER
Asan Medical Center
Phase 2 Active not recruiting
NCT04143152 2024-04-23
Pancreatic Cancer Biomarker Study
Van Andel Research Institute
Active not recruiting